LONDON – In January 2013, Thomson Reuters Cortellis for Competitive Intelligence highlighted five drugs to watch that were predicted to achieve significant regulatory milestones and produce sales of more than $1 billion within five years.

All five met their main anticipated milestones, although only four are now expected to reach blockbuster status.

Consensus sales forecasts for the drugs expected to enter the market in 2014 tend to suggest that the vast majority will have sales of less than $1 billion by 2019. Three, however, are bucking this trend.

Editor’s note: To read this article, which is derived from our life sciences solutions and experts at Thomson Reuters Cortellis for Competitive Intelligence, click here.